Education
About Us
Working with TipRanks
Follow Us
Alligator Bioscience AB (SE:ATORX)
:ATORX
RESEARCH TOOLSreports
Top Page
Alligator Bioscience AB
(LSE:ATORX)
Rating:39Underperform
Price Target:―
Alligator Bioscience AB (ATORX) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr162.19M
Dividend YieldN/A
Average Volume (3M)373.64K
Price to Earnings (P/E)―
Beta (1Y)1.12
Revenue Growth-8.47%
EPS GrowthN/A
CountrySE
Employees33
SectorHealthcare
Sector Strength48
IndustryBiotechnology
Share Statistics
EPS (TTM)-1108.38
Shares Outstanding34,803,898
10 Day Avg. Volume548,724
30 Day Avg. Volume373,639
Financial Highlights & Ratios
PEG Ratio-0.15
Price to Book (P/B)4.81
Price to Sales (P/S)0.00
P/FCF Ratio-6.87
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Alligator Bioscience AB Business Overview & Revenue Model
Company DescriptionAlligator Bioscience AB (publ), a research-based biotechnology company, develops antibody-based drugs for cancer treatment in Sweden. It develops products using its technology platforms, including ALLIGATOR-GOLD and ALLIGATOR-FAB, a proprietary human antibody library that contains approximately 60 billion unique antibody fragments; FIND, a molecular evolution technology for optimization of antibodies and other proteins; and RUBY, a bispecific antibody format. The company develops Mitazalimab, an immunostimulatory CD40 antibody, which has completed Phase I clinical trial for the treatment of metastatic cancer; and ATOR-1017, an immunostimulatory antibody, which is in phase I clinical trial that binds to the receptor 4-1BB in tumor-specific T cells. Its drug candidates in the preclinical development stage include ALG.APV-527, a bispecific 4-1BB and 5T4 antibody for the treatment of cancer. The company also holds a stake in clinical project Biosynergy (AC101), which is in phase I clinical trial. It has a partnership agreement with Aptevo Therapeutics Inc. for the co-development of ALG.APV-527; and a research collaboration with MacroGenics, Inc. to develop a novel immunotherapy. The company also has a joint research agreement with BioArctic AB (publ) to employ proprietary antibody generation technologies for developing new product candidates; and a research collaboration and license agreement with the Orion Corporation to discover and develop new bispecific antibody cancer therapeutics. Alligator Bioscience AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.
How the Company Makes MoneyAlligator Bioscience AB generates revenue primarily through strategic collaborations and licensing agreements with larger pharmaceutical companies. These partnerships often provide upfront payments, milestone payments upon reaching certain clinical or regulatory achievements, and royalties on future sales of successfully developed therapies. Additionally, the company may receive funding through government grants and research collaborations to support its R&D initiatives. The development and commercialization of its proprietary and partnered drug candidates are key drivers of its revenue model.
Alligator Bioscience AB Financial Statement Overview
Summary
Alligator Bioscience AB faces significant financial challenges. The income statement reveals persistent losses and declining revenues, while the balance sheet indicates high leverage and negative equity. Cash flow issues persist, with negative operating and free cash flows. The company needs strategic changes to improve profitability and financial stability.Income Statement
The company shows declining revenue trends, with a significant drop in the most recent TTM period. Gross profit margins are negative, indicating cost issues. Net profit margins are also deeply negative, raising concerns about profitability. EBIT and EBITDA margins are both negative, reflecting operational challenges.45
Neutral
Balance Sheet
The company's balance sheet is highly leveraged with a negative stockholders' equity, posing financial stability risks. The debt-to-equity ratio is not meaningful due to negative equity, and the equity ratio is negative, indicating insolvency issues. Return on equity is also negative due to sustained losses.30
Negative
Cash Flow
Operating cash flow is negative, highlighting cash management challenges. Free cash flow is consistently negative, though recent financing activities have temporarily improved liquidity. The operating cash flow to net income ratio suggests operational inefficiencies.40
Negative
| Breakdown | |||||
| TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 55.97M | 57.77M | 58.11M | 35.70M | 12.94M | 4.35M | Gross Profit |
| 21.62M | 57.77M | 58.11M | -112.03M | -74.04M | -77.97M | EBIT |
| -213.49M | -229.14M | -248.98M | -192.79M | -141.56M | -144.30M | EBITDA |
| -101.66M | -165.47M | -237.61M | -180.99M | -130.39M | -131.46M | Net Income Common Stockholders |
| -179.49M | -233.89M | -248.59M | -193.40M | -141.74M | -143.61M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 28.85M | 64.31M | 66.12M | 97.31M | 278.15M | 103.34M | Total Assets |
| 68.80M | 104.34M | 118.45M | 169.58M | 333.20M | 151.94M | Total Debt |
| 41.86M | 43.57M | 16.10M | 24.50M | 9.74M | 12.07M | Net Debt |
| 13.01M | -20.74M | -50.02M | -72.80M | -268.41M | -91.27M | Total Liabilities |
| 167.88M | 234.93M | 106.59M | 80.53M | 50.93M | 36.69M | Stockholders Equity |
| -99.08M | -130.59M | 11.86M | 89.05M | 282.27M | 115.24M |
| Cash Flow | Free Cash Flow | ||||
| -187.89M | -212.43M | -191.74M | -173.05M | -127.08M | -141.45M | Operating Cash Flow |
| -186.43M | -212.43M | -189.28M | -172.61M | -127.03M | -141.35M | Investing Cash Flow |
| 2.21M | 0.00 | -2.46M | -440.00K | -45.00K | 156.89M | Financing Cash Flow |
| 174.59M | 211.27M | 161.56M | -7.83M | 301.80M | -6.15M |
Alligator Bioscience AB Technical Analysis
Neutral
4.48
Price Trends
4.63
Negative
19.23
Negative
49.51
Negative
Market Momentum
-0.83
Negative
44.73
Neutral
49.11
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ATORX, the sentiment is Neutral. The current price of 4.48 is above the 20-day moving average (MA) of 4.11, below the 50-day MA of 4.63, and below the 200-day MA of 49.51, indicating a neutral trend. The MACD of -0.83 indicates Negative momentum. The RSI at 44.73 is Neutral, neither overbought nor oversold. The STOCH value of 49.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:ATORX.
Alligator Bioscience AB Peers Comparison
Overall Rating
UnderperformOutperform
Sector (53)
Financial Indicators
Performance Comparison
SE:ATORX
Alligator Bioscience AB
4.48
-97.83
-95.62%
DE:8N1
Biosergen AB
0.04
0.01
33.33%
DE:1XT
Xintela AB
0.03
0.02
200.00%
DE:8E8
Elicera Therapeutics AB
0.45
0.35
350.00%
DE:5JD0
ExpreS2ion Biotech Holding AB
1.82
-0.82
-31.06%
DE:BTPC
Active Biotech AB
0.02
0.00
0.00%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.